See more : Kaishan Group Co., Ltd. (300257.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Concord Medical Services Holdings Limited (CCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concord Medical Services Holdings Limited, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Curo Co.,Ltd. (015590.KS) Income Statement Analysis – Financial Results
- Wanda Hotel Development Company Limited (0169.HK) Income Statement Analysis – Financial Results
- Millrock Resources Inc. (0V6Y.L) Income Statement Analysis – Financial Results
- AdvanceTC Limited (ATCLF) Income Statement Analysis – Financial Results
- Jet.AI Inc. (JTAI) Income Statement Analysis – Financial Results
Concord Medical Services Holdings Limited (CCM)
About Concord Medical Services Holdings Limited
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 537.40M | 472.09M | 485.63M | 223.01M | 198.36M | 190.90M | 330.98M | 455.04M | 616.49M | 606.88M | 563.12M | 455.65M | 450.13M | 389.52M | 292.44M | 171.79M |
| Cost of Revenue | 614.01M | 624.49M | 542.53M | 209.93M | 214.19M | 171.14M | 232.98M | 286.54M | 353.34M | 274.56M | 217.66M | 164.52M | 159.42M | 122.70M | 87.56M | 45.60M |
| Gross Profit | -76.61M | -152.41M | -56.90M | 13.08M | -15.83M | 19.76M | 98.00M | 168.50M | 263.15M | 332.32M | 345.47M | 291.13M | 290.71M | 266.82M | 204.88M | 126.19M |
| Gross Profit Ratio | -14.26% | -32.28% | -11.72% | 5.87% | -7.98% | 10.35% | 29.61% | 37.03% | 42.69% | 54.76% | 39.77% | 49.68% | 64.58% | 68.50% | 70.06% | 73.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 308.71M | 311.16M | 347.75M | 294.82M | 315.13M | 291.85M | 237.65M | 205.91M | 132.95M | 53.58M | 84.51M | 61.11M | 114.40M | 70.01M | 29.82M | 18.87M |
| Selling & Marketing | 56.30M | 61.48M | 53.68M | 25.76M | 30.24M | 21.72M | 43.61M | 70.09M | 112.82M | 95.10M | 104.67M | 53.91M | 37.45M | 17.15M | 7.68M | 5.50M |
| SG&A | 386.38M | 372.64M | 401.42M | 320.58M | 345.38M | 313.57M | 281.25M | 276.00M | 245.77M | 148.67M | 189.17M | 115.02M | 151.85M | 87.16M | 37.50M | 24.37M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 8.50M | 76.09M | 5.43M | 28.60M | 61.12M | 23.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 386.38M | 372.64M | 401.42M | 329.08M | 421.46M | 319.01M | 309.85M | 337.13M | 268.89M | 148.67M | 189.17M | 103.39M | 151.85M | 87.16M | 37.50M | 24.37M |
| Cost & Expenses | 1.00B | 997.13M | 943.95M | 539.01M | 635.66M | 490.14M | 542.83M | 623.67M | 622.23M | 423.23M | 406.83M | 267.92M | 311.27M | 209.86M | 125.06M | 69.96M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.60M | 13.36M | 7.87M | 948.00K | 430.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.45M | 7.45M | 6.89M | 7.46M |
| Depreciation & Amortization | 118.83M | 123.19M | 94.46M | 70.79M | 56.35M | 45.02M | 89.45M | 127.81M | 157.25M | 198.07M | 179.64M | 148.58M | 120.64M | 109.69M | 78.17M | 38.13M |
| EBITDA | -344.16M | -401.86M | -363.86M | -236.72M | -304.85M | -248.79M | -93.80M | 20.31M | 174.63M | 381.72M | 335.94M | 332.63M | -161.31M | 291.93M | 246.29M | 140.38M |
| EBITDA Ratio | -48.65% | -123.11% | -68.24% | -92.56% | -132.90% | -110.82% | -21.79% | 15.01% | 11.01% | 36.40% | 21.26% | 32.51% | 33.82% | 46.79% | 57.56% | 81.72% |
| Operating Income | -462.99M | -525.05M | -458.32M | -316.00M | -437.29M | -299.24M | -211.86M | -168.63M | -5.74M | 183.65M | 156.30M | 184.05M | 138.86M | 179.67M | 167.38M | 101.83M |
| Operating Income Ratio | -86.15% | -111.22% | -94.38% | -137.89% | -220.45% | -156.76% | -64.01% | -37.06% | -0.93% | 30.26% | 17.92% | 30.71% | 30.85% | 46.12% | 57.24% | 59.27% |
| Total Other Income/Expenses | -92.61M | -314.85M | -70.92M | -125.65M | 46.22M | 74.00M | -42.04M | -35.97M | 489.00K | -8.00M | -12.03M | -2.91M | -3.73M | -4.88M | -6.16M | 578.00K |
| Income Before Tax | -555.59M | -839.90M | -529.24M | -441.65M | -391.08M | -225.25M | -253.90M | -204.60M | -5.25M | 175.65M | 144.27M | 181.14M | -165.03M | 174.79M | 161.22M | 102.40M |
| Income Before Tax Ratio | -103.39% | -177.91% | -108.98% | -198.04% | -197.15% | -117.99% | -76.71% | -44.96% | -0.85% | 28.94% | 17.36% | 29.41% | -36.66% | 44.87% | 55.13% | 59.61% |
| Income Tax Expense | 24.57M | 70.91M | 6.57M | 37.62M | 38.99M | 34.05M | 31.79M | 60.49M | 74.03M | 80.85M | 63.84M | 54.25M | 46.32M | 43.87M | 36.40M | 23.34M |
| Net Income | -297.66M | -489.66M | -271.43M | -309.99M | -307.05M | -234.88M | -284.32M | -261.87M | -78.30M | 124.71M | 85.89M | 123.24M | -215.00M | 129.40M | 124.83M | 79.07M |
| Net Income Ratio | -55.39% | -103.72% | -168.98% | -300.39% | -278.54% | -188.18% | -85.90% | -57.55% | -12.70% | 16.35% | 13.34% | 27.05% | -47.77% | 33.22% | 42.69% | 46.03% |
| EPS | -68.14 | -112.09 | -187.85 | -153.35 | -127.27 | -82.83 | -65.57 | -60.14 | -17.46 | 22.08 | 16.69 | 2.67 | -4.53 | 2.67 | 1.86 | -25.89 |
| EPS Diluted | -68.14 | -112.09 | -187.85 | -153.35 | -127.27 | -82.83 | -65.57 | -60.14 | -17.46 | 21.95 | 16.69 | 2.67 | -4.53 | 2.67 | 1.86 | -25.89 |
| Weighted Avg Shares Out | 4.37M | 4.37M | 1.44M | 2.02M | 2.41M | 2.84M | 4.34M | 4.35M | 4.48M | 5.68M | 5.15M | 46.07M | 47.42M | 48.68M | 24.88M | 19.16M |
| Weighted Avg Shares Out (Dil) | 4.37M | 4.37M | 4.37M | 4.37M | 4.34M | 4.34M | 4.34M | 4.35M | 4.48M | 4.51M | 4.50M | 46.07M | 47.42M | 48.68M | 24.88M | 19.16M |
Concord Medical Schedules 2024 Annual Meeting of Shareholders
Concord Medical Reports Financial Results for the First Half of 2024
Canagold Completes Resource Expansion Drilling Program at New Polaris with Additional Strong Mineralization Intercepts
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
Canagold Resources Ltd. Announces Voting Results From Annual General Meeting
Canagold Initiates Resource Expansion Drilling at New Polaris Project
Concord Medical Files 2023 Annual Report on Form 20-F
Canagold Resources Ltd. Announces Closing of $4.1M Charity Flow Through Financing
Source: https://incomestatements.info
Category: Stock Reports